Literature DB >> 30124200

Suitability of EBT3 GafChromic film for quality assurance in MR-guided radiotherapy at 0.35 T with and without real-time MR imaging.

Danique L J Barten1, Daan Hoffmans, Miguel A Palacios, Stan Heukelom, Leo J van Battum.   

Abstract

The 0.35 T 60Co MRIdian system (ViewRay Inc., Mountain View) has been in clinical use in our institution since May 2016. For quality assurance (QA) of dose delivery and end-to-end testing for this machine, a reliable dosimeter is required. However, it is possible that a magnetic field may cause perturbations to dosimetry measurements. For static magnetic fields, there is conflicting information in the literature concerning EBT film behaviour, while for real-time MR imaging such information is not available at all. The purpose of this study was to investigate the suitability of EBT3 GafChromic film for MRIdian QA, both with and without real-time MR imaging. EBT3 film sheets were irradiated in water using the MRIdian and a conventional linear accelerator (Linac) for reference. Dose calibration measurements were first performed up to 8 Gy for both machines. The MRIdian measurements were performed with and without real-time MR imaging. Second, film sheets were irradiated at seven different angles with respect to the B0-field. Optical density and dose values were analysed for the three colour channels. In both the film dose-response and B0-field orientation measurements, the mean dose values were within the 1% uncertainty range of prescribed dose values for the red and green channels, for both machines. There were no dose deviations detected between the MRIdian and Linac film measurements, nor for different B0-field orientations. In addition, the film dose-response measurements during real-time imaging were within 1.5% of the reference Linac measurements. EBT3 GafChromic film can be used for absolute dosimetry during real-time MR imaging independent of its orientation in the B0-field. This makes it a suitable dosimeter for patient-specific QA measurements and end-to-end testing of 0.35 T MRI-radiotherapy devices.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30124200     DOI: 10.1088/1361-6560/aad58d

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

1.  Multichannel Film Dosimetry for Quality Assurance of Intensity Modulated Radiotherapy Treatment Plans Under 0.35 T Magnetic Field.

Authors:  Gorkem Gungor; Latif Korkmaz; Namik Kayalilar; Gokhan Aydin; Bulent Yapici; Teuta Zoto Mustafayev; Banu Atalar; Enis Ozyar
Journal:  Cureus       Date:  2020-03-20

2.  Dose response of three-dimensional silicone-based radiochromic dosimeters for photon irradiation in the presence of a magnetic field.

Authors:  Morten B Jensen; Peter Balling; Simon J Doran; Jørgen B B Petersen; Isak H Wahlstedt; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2020-10-19

3.  A clinical validation of the MR-compatible Delta4 QA system in a 0.35 tesla MR linear accelerator.

Authors:  Vimal Desai; John Bayouth; Jennifer Smilowitz; Poonam Yadav
Journal:  J Appl Clin Med Phys       Date:  2021-03-05       Impact factor: 2.102

Review 4.  Medical physics challenges in clinical MR-guided radiotherapy.

Authors:  Christopher Kurz; Giulia Buizza; Guillaume Landry; Florian Kamp; Moritz Rabe; Chiara Paganelli; Guido Baroni; Michael Reiner; Paul J Keall; Cornelis A T van den Berg; Marco Riboldi
Journal:  Radiat Oncol       Date:  2020-05-05       Impact factor: 3.481

5.  Characterizing magnetically focused contamination electrons by off-axis irradiation on an inline MRI-Linac.

Authors:  Elizabeth Patterson; Bradley M Oborn; Dean Cutajar; Urszula Jelen; Gary Liney; Anatoly B Rosenfeld; Peter E Metcalfe
Journal:  J Appl Clin Med Phys       Date:  2022-03-25       Impact factor: 2.243

6.  Clinical utility of Gafchromic film in an MRI-guided linear accelerator.

Authors:  Ilma Xhaferllari; Joshua P Kim; Ruchira Liyanage; Chang Liu; Dongsu Du; Anthony Doemer; Indrin J Chetty; Ning Wen
Journal:  Radiat Oncol       Date:  2021-06-26       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.